X4 Pharmaceuticals, Inc.
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 93
- Market Cap
- $117.9M
- Website
- http://www.x4pharma.com
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- X4 Pharmaceuticals
- Target Recruit Count
- 150
- Registration Number
- NCT06056297
- Locations
- ๐ฌ๐ช
LTD "Israeli-Georgian Medical Research Clinic Healthycore", Tbilisi, Georgia
๐ฌ๐ชLEPL The First University Clinic of Tbilisi State Medical University, Tbilisi, Georgia
๐ช๐ธHospital Universitario Son Espases, Mallorca, Spain
A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4
- Conditions
- Interventions
- First Posted Date
- 2020-02-18
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- X4 Pharmaceuticals
- Target Recruit Count
- 16
- Registration Number
- NCT04274738
- Locations
- ๐บ๐ธ
Dana Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธMass General Hospital Cancer Center, Boston, Massachusetts, United States
๐ฌ๐ทUniversity of Athens, Athens, Greece
A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders
- First Posted Date
- 2019-11-06
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- X4 Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT04154488
- Locations
- ๐บ๐ธ
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
๐บ๐ธUniversity of Washington, Seattle, Washington, United States
๐บ๐ธUSF Health Department of Pediatrics, Saint Petersburg, Florida, United States
Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome
- First Posted Date
- 2019-06-21
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- X4 Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT03995108
- Locations
- ๐ฆ๐บ
Wesley Hospital, Auchenflower, Queensland, Australia
๐ญ๐บUniversity of Debrecen, Affiliated Department of Infectology, Debrecen, Hajdu-Bihar, Hungary
๐ซ๐ทCHU de Lyon, Institut d'Hematologie et d'Oncologie Pediatrique, Lyon, Rhne, France
A Retrospective and Prospective Natural History Study of Patients With WHIM Syndrome
- Conditions
- First Posted Date
- 2017-03-22
- Last Posted Date
- 2018-12-07
- Lead Sponsor
- X4 Pharmaceuticals
- Registration Number
- NCT03087370
A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome
- First Posted Date
- 2016-12-29
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- X4 Pharmaceuticals
- Target Recruit Count
- 8
- Registration Number
- NCT03005327
- Locations
- ๐บ๐ธ
University of Washington Medical Center, Seattle, Washington, United States
๐ฆ๐บSt. Vincent's Hospital, Fitzroy, Victoria, Australia
Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma
- First Posted Date
- 2016-10-04
- Last Posted Date
- 2022-12-29
- Lead Sponsor
- X4 Pharmaceuticals
- Target Recruit Count
- 9
- Registration Number
- NCT02923531
X4P-001 and Pembrolizumab in Patients With Advanced Melanoma
- First Posted Date
- 2016-07-06
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- X4 Pharmaceuticals
- Target Recruit Count
- 16
- Registration Number
- NCT02823405
- Locations
- ๐บ๐ธ
Clinical Site, Salt Lake City, Utah, United States
A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers
- First Posted Date
- 2016-02-12
- Last Posted Date
- 2018-12-07
- Lead Sponsor
- X4 Pharmaceuticals
- Target Recruit Count
- 15
- Registration Number
- NCT02680782
- Locations
- ๐บ๐ธ
Covance CRU, Inc., Daytona Beach, Florida, United States
Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma
- First Posted Date
- 2016-01-29
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- X4 Pharmaceuticals
- Target Recruit Count
- 74
- Registration Number
- NCT02667886